Navin Moleculor has appointed Dr. Vijay Kaiwar as CEO-CDMO, effective 25 August 2025, with the formal assumption of duties on 21 September 2025. Based at Dewas, he will report to Managing Director, Mr. Nitin Kulkarni. Dr. Kaiwar brings more than
“A strategic partnerships is not a transactional relationship – it’s a partnership that should last. If we incentivise through co-investments and risk sharing, the partner can grow their business while enabling us to achieve cost and volume targets.” – Shilpi
PolyPeptide Group AG has reached a key milestone in its Malmö, Sweden expansion by completing the delivery and installation of pre-built modules at the site. The development is part of a modular construction project announced in January 2025, which aims
AGC Pharma Chemicals has inaugurated the €110 million expansion of its factory in Malgrat de Mar, Barcelona. The investment, which exceeded the initially announced €90 million, was completed one year later than scheduled. The company stated that the new facilities
Merck has officially inaugurated two new facilities in Ireland and Germany as part of its global expansion strategy, representing a combined investment of more than €300 million. In Blarney, Ireland, the company has invested €150 million in a life science
Kindeva has officially opened its expanded metered-dose inhaler (MDI) manufacturing facility at Charnwood Campus in Loughborough, marking an investment in sustainable inhalation therapy manufacturing as the industry transitions toward environmentally-friendly propellants. PharmaSource attended the opening ceremony, which featured a comprehensive
Mikart, LLC, a contract development and manufacturing organisation (CDMO), and Nano PharmaSolutions, Inc. (NPS), a nanodrug delivery pharmaceutical company, have reported encouraging interim results from the ongoing Phase 1 clinical trial of NT-301. The proprietary powder nasal spray is being
FUJIFILM Biotechnologies, a contract development and manufacturing organisation (CDMO), has announced an expansion of its global partnership with immunology company argenx SE. Under the agreement, FUJIFILM Biotechnologies will begin manufacturing efgartigimod drug substance in Holly Springs, North Carolina, in 2028.
“In pharmaceutical consulting everybody’s just doing their own thing. It’s the Wild West compared to what it should be.” – Ray Sison Ray Sison, founder of SCxCMC exclusively speaks to the PharmaSource podcast about the launch of the Society of
Lilly has announced plans to invest $5 billion to establish a new manufacturing facility west of Richmond, Virginia. The site will be the company’s first dedicated, fully integrated active pharmaceutical ingredient (API) and drug product facility for its bioconjugate platform
